Zacks: Analysts Anticipate Adaptimmune Therapeutics PLC – (ADAP) Will Post Earnings of -$0.27 Per Share

Equities analysts expect that Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) will post earnings of ($0.27) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Adaptimmune Therapeutics’ earnings, with estimates ranging from ($0.35) to ($0.18). Adaptimmune Therapeutics reported earnings of ($0.29) per share in the same quarter last year, which would suggest a positive year over year growth rate of 6.9%. The business is scheduled to issue its next quarterly earnings report on Thursday, March 21st.

On average, analysts expect that Adaptimmune Therapeutics will report full year earnings of ($0.98) per share for the current year, with EPS estimates ranging from ($1.21) to ($0.84). For the next fiscal year, analysts forecast that the company will report earnings of ($1.24) per share, with EPS estimates ranging from ($1.50) to ($0.94). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow Adaptimmune Therapeutics.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.09. The business had revenue of $40.79 million during the quarter, compared to analysts’ expectations of $29.41 million. Adaptimmune Therapeutics had a negative net margin of 139.57% and a negative return on equity of 46.63%.

A number of research analysts have recently issued reports on ADAP shares. BidaskClub upgraded shares of Adaptimmune Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, August 24th. Cowen reiterated a “buy” rating on shares of Adaptimmune Therapeutics in a report on Thursday, August 2nd. Guggenheim initiated coverage on shares of Adaptimmune Therapeutics in a report on Monday, September 17th. They set a “buy” rating for the company. Raymond James dropped their price target on shares of Adaptimmune Therapeutics from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday, October 22nd. Finally, ValuEngine lowered shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. Adaptimmune Therapeutics presently has an average rating of “Buy” and a consensus price target of $15.44.

NASDAQ:ADAP traded down $0.48 during trading hours on Friday, reaching $6.18. The company had a trading volume of 682,729 shares, compared to its average volume of 523,246. The stock has a market capitalization of $616.54 million, a price-to-earnings ratio of -7.73 and a beta of 2.02. Adaptimmune Therapeutics has a twelve month low of $5.73 and a twelve month high of $14.63.

In related news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $13.79, for a total transaction of $344,750.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ali Behbahani purchased 12,000,000 shares of the company’s stock in a transaction that occurred on Friday, September 7th. The shares were purchased at an average cost of $1.67 per share, for a total transaction of $20,040,000.00. The disclosure for this purchase can be found here. 26.47% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Baillie Gifford & Co. lifted its position in shares of Adaptimmune Therapeutics by 18.2% during the second quarter. Baillie Gifford & Co. now owns 3,033,261 shares of the biotechnology company’s stock valued at $36,005,000 after purchasing an additional 467,852 shares in the last quarter. BlackRock Inc. lifted its position in shares of Adaptimmune Therapeutics by 2.5% during the first quarter. BlackRock Inc. now owns 806,952 shares of the biotechnology company’s stock valued at $9,062,000 after purchasing an additional 19,765 shares in the last quarter. Frontier Capital Management Co. LLC raised its position in Adaptimmune Therapeutics by 351.1% in the third quarter. Frontier Capital Management Co. LLC now owns 698,694 shares of the biotechnology company’s stock worth $9,474,000 after acquiring an additional 543,809 shares during the period. Stanley Laman Group Ltd. bought a new stake in Adaptimmune Therapeutics in the third quarter worth about $7,665,000. Finally, JPMorgan Chase & Co. raised its position in Adaptimmune Therapeutics by 786.0% in the first quarter. JPMorgan Chase & Co. now owns 185,660 shares of the biotechnology company’s stock worth $2,085,000 after acquiring an additional 164,704 shares during the period. 58.99% of the stock is currently owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

See Also: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Adaptimmune Therapeutics (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply